Immunogen, Inc.

NASDAQ:IMGN   3:59:57 PM EDT
5.60
+0.15 (+2.75%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)977.22M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$39.11 Million
Adjusted EPS-$0.09
See more estimates
10-Day MA$5.61
50-Day MA$5.16
200-Day MA$4.37
See more pivots

IMMUNOGEN INC Stock, NASDAQ:IMGN

830 WINTER ST, WALTHAM, MA 02451
United States of America
Phone: (781)895-0600
Number of Employees: 296

Description

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; Takeda Pharmaceutical Company Limited; Merck; and CytomX Therapeutics, Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.